In-licensed, co-promoted and own products

Partners

Oncology Treatment of viral infections Autoimmune diseases

Avastin; Capecitabin-TL; Faslodex; Gefitinib-TL; Granisetron-TL; Abacavir-AVS; Arlansa; Atazanavir-TL; Coronavir; Darunavir;
Herceptin; Inlyta; Ixempra; Kadcyla; Keytruda; Ondasetron; Emtricitabine-TL; Efavirenz-TL; Isentress; Kaletra; Lamivudine- Artlegia; Aubagio; Enbrel; Femorix; Glatirate; Humira; Jaquinus;
Pemetrexed-TL; Perjeta; Pomalidomide-TL; Redditux; Sprycel; ZTS; Nevirapine-TL; Maviret; Pegasys; PegIntron; Ritonavir; Remicade; Ranvec
Tarceva; Temozolomide-TL;Yondelis, Xeloda Saquinavir-TL; Tenofovir-TL; Viekira Pak; Zidovudine; Zilam

Antimicrobial therapy Contrast agents Women’s health

Amikacin; Cancidas; Ciprofloxacin; Cycloserine; Deltyba;
Iomeron; Multihance; Optiray; Prohance; Sonovue Elonva; Menogon; Menopur; Orgalutran; Pregnyl; Puregon
Fluconazole; Fosmicin; Invanz; Noxafil; Metronidazole;
Moxifloxacin; Rezonisat Spectracef; Vancomycin; Vibativ

Nephrology Pulmonology Others

Zemplar; Kalimeit; Mircera; Cinacalcet TL Bretaris; Duaklir,: Fasenra Adant; Aldurazyme; Bridion; Cellcept; Gamunex; Humalog;
Humulin; Januvia; Janumet; Kanarb; Keppra; Myfortic;
Plasbumin; Privigen; Recormon; Sevorane

R-PHARM GROUP
R-Pharm Research
& Development
Healthy and robust pipeline
● R-Pharm pipeline ● In-licensed pipeline • Product is studied in COVID-19
therapy

Early Pre-clinical Clinical Marketing

Therapeutic area Product Filing
development studies studies authorization
RPH-001 ●●●●●●●●● ●●●●●●●●● ●●●●●●●●●
RPH-002 ●●●●●●●●● ●●●●●●●●● ●●●●●●●●●
ONC1-0013B ●●●●●●●●● ●●●●●●●●● ●●●●●●
RPH-120 ●●●●●●●●● ●●●●●●●●●
ZD19-0144 ●●●●●●●●● ●●●●●●●●●
ZD19-0115 ●●●●●●●●● ●●●●●●●●●
Oncology
RPH-030 ●●●●●●●●●
RPH-041 ●●●●●●●●●
RPH-075 ●●●●●●●●●
RPH-236 ●●●●●●●●●
Ixabepilone ●●●●●●●●● ●●●●●●●●● ●●●●●●●●● ●●●●●●●●● ●●●●●●●●●
Trabectedin ●●●●●●●●● ●●●●●●●●● ●●●●●●●●● ●●●●●●●●● ●●●●●●●●●
Radotinib* ●●●●●●●●● ●●●●●●●●● ●●●●●●●●● ●●●●●●●●●
Favipiravir ●●●●●●●●● ●●●●●●●●● ●●●●●●●●● ●●●●●●●●● ●●●●●●●●●
Delamanid ●●●●●●●●● ●●●●●●●●● ●●●●●●●●● ●●●●●●●●● ●●●●●●●●●
Narlaprevir ●●●●●●●●● ●●●●●●●●● ●●●●●●●●● ●●●●●●●●● ●●●●●●●●●
Antibacterial &
antiviral Nemonoxacin ●●●●●●●●● ●●●●●●●●● ●●●●●●●●● ●●●●●●●●●
Albuvirtide ●●●●●●●●● ●●●●●●●●● ●●●●●●●●●
Cefilavancin ●●●●●●●●● ●●●●●●●●● ●●●●●●●●●
 Healthy and robust pipeline
● R-Pharm pipeline ● In-licensed pipeline • Product is studied in COVID-19
therapy

Early Pre-clinical Clinical Marketing

Therapeutic area Product Filing
development studies studies authorization
RPH-104* ●●●●●●●●● ●●●●●●●●● ●●●●●●●●●
Anti-inflammatory / RPH-035 ●●●●●●●●●
Autoimmune
RPH-040 ●●●●●●●●●
Olokizumab * ●●●●●●●●● ●●●●●●●●● ●●●●●●●●● ●●●●●●●●● ●●●●●●●●●
AZD_Sputnik combo ●●●●●●●●● ●●●●●●●●● ●●●●●●
Vaccines HPV vaccine ●●●●●●●●● ●●●●●●●●●
MGU COVID-19 ●●●●●●●●● ●●●●●●●●●
RPH-026 ●●●●●●●●●
RPH-137* ●●●●●●●●●
RPH-239* ●●●●●●●●●
Fimasartan ●●●●●●●●● ●●●●●●●●● ●●●●●●●●● ●●●●●●●●● ●●●●●●●●●
Other
Imidafenacin ●●●●●●●●● ●●●●●●●●● ●●●●●●●●● ●●●●●●●●●
Odelepran ●●●●●●●●● ●●●●●●●●● ●●●●●●●●● ●●●●●●●●●
Remimazolam ●●●●●●●●● ●●●●●●●●● ●●●●●●●●● ●●●●●●●●●
Refralon (tabs) ●●●●●●●●● ●●●●●●●●● ●●●
R-Pharm Commercial
Operations
R-Pharm has well-established Market Access capabilities
Nosology Products Partners

“VZN” Program
§ Multiple sclerosis
(federal budget)

§ Breast cancer
§ Lung cancer
§ Hematology
§ Secondary hyper-
Reimbursement / parathyroidism
EDL § Hyperactive Bladder
(regional budget) § Hepatitis C
§ HIV
§ Antibiotics
§ Rheumatoid arthritis
§ Psoriasis CORONAVIR
favipiravir
§ Inhalation
anesthesia olocizumab
Deltyba
§ Bronchial asthma delamani
§ COVID-19 d
§ Tuberculosis
R-PHARM GROUP
Successful partnerships and recent launches
Sell Out, M RUB
25 000

20 000

15 000

10 000

5 000

-
2017 2018 2019 2020 YTD
10'2021

Source: internal reporting

R-PHARM GROUP
 R-Pharm
Manufacturing
R-Pharm plants (1)

9
R-Pharm plants (2)

10
High Business Standards
Risk management
and compliance
R-Pharm Group applies high ethics standards, follows
international principles of business conduct and has
zero tolerance towards corruption.
The success of our business is largely related to the fact
that all the employees of R-Pharm are fully committed
to upholding high standards of business integrity,
honesty and transparency in all their business activities.
R-PHARM GROUP
TRACE INTERNATIONAL certificate obtained in
2007 and prolonged ever since
Code of Ethical business conduct and Anticorruption
policy established in 2012 and applied ever since
Chief compliance officer reporting directly to CEO in
place since 2012
Numerous external audits conducted by
representatives of the Big Four
FCPA agreements signed with the majority of
business partners
Standard operational procedures applied at every
stage of every business process
Compulsory compliance training for employees in
place since 2013
Quality assurance priority

Pharmaceutical business relates directly to health and well-being of people. That is why it is so
important to achieve the highest quality of products and make sure that these kind of risks are
961
close to nonexistent. To assure this R-Pharm facilities and business processes have been tuned in employees occupied in
manufacturing completed additional
accordance with both all Russian and international standards of quality. quality assurance training*

R-Pharm manufacturing sites are regularly subjected to external audits effectuated by regulatory
authorities and companies-partners.

>60 >13
successfully completed internationally recognized licenses, certificates Compliance with the latest
external quality audits* and other quality assurance documents international quality standards:

R-PHARM GROUP
* R-Pharm’s data for 2015-2018
GСP GMP GDP GEP
End-to-end
solutions
 End-to-end solutions

Our team of professionals tackle rapid changes in the regulatory, clinical and commercial landscape in
which they operate to create a tailor-made strategy and guide your product to the Russian market.

Clinical and
Preclinical Regulatory
Research Approval Registration Value Creation Manufacturing

Marketing Commercial Distribution Deliver

Launch Commercial
Success

R-PHARM GROUP